Last 7 days
0.7%
Last 30 days
-27.7%
Last 90 days
-23.9%
Trailing 12 Months
-44.3%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-09-15 | Bell Michael Brian | sold (taxes) | -12,609 | 29.53 | -427 | chief financial officer |
2023-09-15 | Bell Michael Brian | acquired | - | - | 1,233 | chief financial officer |
2023-09-15 | POTTER MYRTLE S | acquired | - | - | 69.00 | - |
2023-09-12 | Kalia Kumud | sold | -69,253 | 32.59 | -2,125 | chief information officer |
2023-09-09 | Kalia Kumud | sold (taxes) | -76,308 | 33.72 | -2,263 | chief information officer |
2023-09-09 | Saia John G. | sold (taxes) | -10,183 | 33.72 | -302 | chief legal officer |
2023-09-09 | Kalia Kumud | acquired | - | - | 6,544 | chief information officer |
2023-09-09 | Chudova Darya | acquired | - | - | 2,908 | chief technology officer |
2023-09-09 | Chudova Darya | sold (taxes) | -33,922 | 33.72 | -1,006 | chief technology officer |
2023-09-09 | Merrill Amelia | sold (taxes) | -12,240 | 33.72 | -363 | svp, people |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | reduced | -21.56 | 120,682 | 2,703,770 | 0.02% |
2023-09-21 | Baystate Wealth Management LLC | new | - | 2,864 | 2,864 | -% |
2023-09-20 | BARCLAYS PLC | added | 33.08 | 3,691,000 | 7,264,000 | -% |
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | 149 | 430 | -% |
2023-09-07 | Triatomic Management LP | reduced | -42.97 | -106,088 | 716,000 | 0.73% |
2023-09-06 | Deep Track Capital, LP | new | - | 53,700,000 | 53,700,000 | 2.49% |
2023-08-24 | Adalta Capital Management LLC | reduced | -0.85 | 987,000 | 2,906,000 | 1.94% |
2023-08-23 | Stonebridge Capital Advisors LLC | new | - | 1,969 | 1,969 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 118 | 799,796 | 1,142,020 | 0.01% |
2023-08-22 | COMERICA BANK | new | - | 64,000 | 64,000 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Mar 10, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 14, 2023 | viking global investors lp | 4.0% | 4,107,644 | SC 13G/A | |
Feb 13, 2023 | capital international investors | 7.7% | 7,879,355 | SC 13G | |
Feb 13, 2023 | capital research global investors | 2.0% | 2,001,782 | SC 13G/A | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.83% | 9,040,240 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 5.4% | 5,495,293 | SC 13G | |
Mar 09, 2022 | blackrock inc. | 4.9% | 4,961,865 | SC 13G/A | |
Feb 11, 2022 | capital research global investors | 7.8% | 7,927,702 | SC 13G | |
Feb 10, 2022 | fmr llc | - | 0 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 19, 2023 | 4 | Insider Trading | |
Sep 19, 2023 | 4 | Insider Trading | |
Sep 13, 2023 | 4 | Insider Trading | |
Sep 12, 2023 | 144 | Notice of Insider Sale Intent | |
Sep 11, 2023 | 4 | Insider Trading | |
Sep 11, 2023 | 4 | Insider Trading | |
Sep 11, 2023 | 4 | Insider Trading | |
Sep 11, 2023 | 4 | Insider Trading | |
Sep 07, 2023 | 8-K | Current Report | |
Sep 06, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
HCA | 67.5B | 61.9B | -10.91% | 34.15% | 11.69 | 1.09 | 3.02% | -11.37% |
LH | 18.2B | 14.1B | -3.48% | -0.57% | 21.87 | 1.29 | -5.68% | -58.27% |
DGX | 13.8B | 9.5B | -6.83% | 1.44% | 17.41 | 1.46 | -10.34% | -46.50% |
MID-CAP | ||||||||
UHS | 8.7B | 13.8B | -6.62% | 41.44% | 12.58 | 0.63 | 5.76% | -10.75% |
EHC | 6.7B | 4.6B | -4.11% | 45.48% | 21.27 | 1.46 | 9.56% | -4.24% |
ENSG | 5.2B | 3.4B | -5.62% | 16.47% | 21.63 | 1.54 | 20.66% | 17.86% |
LHCG | 5.2B | 2.3B | 3.17% | 35.63% | 86.23 | 2.28 | 2.85% | -58.05% |
GH | 3.2B | 510.2M | -27.73% | -44.30% | -6.39 | 6.37 | 25.00% | 4.56% |
AMN | 3.1B | 4.4B | -5.01% | -18.52% | 9.85 | 0.72 | -16.06% | -30.43% |
AMED | 3.0B | 2.2B | -0.58% | -8.34% | 1.3K | 1.36 | 0.61% | -98.34% |
SMALL-CAP | ||||||||
RDNT | 1.9B | 1.5B | -9.98% | 59.13% | -149.89 | 1.27 | 12.20% | -155.34% |
BKD | 737.9M | 3.0B | -6.00% | -10.91% | -7.16 | 0.25 | 11.66% | -12.20% |
ENZ | 68.5M | 71.0M | -13.21% | -34.29% | -1.5 | 0.97 | -36.38% | -594.74% |
XGN | 42.7M | 52.9M | 1.20% | -5.95% | -1.21 | 0.81 | 23.27% | 10.26% |
PMD | 21.3M | 23.6M | -14.52% | -42.66% | -11.24 | 0.9 | -9.62% | -60.46% |
-37.2%
96.9%
85.4%
60%
Y-axis is the maximum loss one would have experienced if Guardant Health was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | 5.8% | 510,159,000 | 482,153,000 | 449,538,000 | 430,755,000 | 408,130,000 | 391,087,000 | 373,653,000 | 343,861,000 | 323,651,000 | 297,885,000 | 286,730,000 | 271,311,000 | 257,590,000 | 245,230,000 | 214,375,000 | 184,351,000 | 145,195,000 | 110,602,000 | 90,639,000 | 77,768,000 | 67,208,000 |
S&GA Expenses | -0.8% | 308,959,000 | 311,519,000 | 299,828,000 | 278,004,000 | 247,862,000 | 221,975,000 | 191,881,000 | 163,570,000 | 138,437,000 | 115,736,000 | 106,513,000 | 97,512,000 | 91,219,000 | 85,643,000 | 78,335,000 | 73,162,000 | 67,824,000 | 59,960,000 | 53,465,000 | 45,907,000 | 40,251,000 |
R&D Expenses | 1.3% | 390,082,000 | 385,178,000 | 373,807,000 | 340,250,000 | 311,201,000 | 289,470,000 | 263,221,000 | 230,482,000 | 195,759,000 | 168,354,000 | 149,862,000 | 135,455,000 | 123,779,000 | 106,992,000 | 86,292,000 | 77,069,000 | 66,753,000 | 58,775,000 | 50,714,000 | 42,182,000 | 35,175,000 |
EBITDA | 100.0% | - | -621,807,000 | -614,910,000 | -551,958,000 | -501,772,000 | -374,508,000 | -359,622,000 | -378,569,000 | -344,577,000 | -298,166,000 | -225,073,000 | -160,460,000 | -103,279,000 | -66,952,000 | -57,131,000 | - | - | - | - | - | - |
EBITDA Margin | 100.0% | - | -1.29 | -1.37 | -1.28 | -1.23 | -0.96 | -0.96 | -1.10 | -1.06 | -1.00 | -0.78 | -0.59 | -0.40 | -0.27 | -0.27 | - | - | - | - | - | - |
Interest Expenses | 0% | 2,577,000 | 2,577,000 | 2,577,000 | 2,576,000 | 2,576,000 | 2,575,000 | 2,577,000 | 6,670,000 | 6,034,000 | 5,400,000 | 4,766,000 | 351,000 | 623,000 | 900,000 | 1,181,000 | 1,159,000 | 1,183,000 | 1,213,000 | 1,251,000 | 1,256,000 | 1,255,000 |
Earnings Before Taxes | 23.6% | -506,779,000 | -663,490,000 | -653,449,000 | -586,417,000 | -531,968,000 | -400,474,000 | -384,470,000 | -404,952,000 | -369,124,000 | -321,337,000 | -245,904,000 | -175,721,000 | -117,411,000 | -80,213,000 | -69,723,000 | -72,361,000 | -82,577,000 | -91,706,000 | -84,225,000 | -74,041,000 | -79,123,000 |
EBT Margin | 100.0% | - | -1.38 | -1.45 | -1.36 | -1.30 | -1.02 | -1.03 | -1.18 | -1.14 | -1.08 | -0.86 | -0.65 | -0.46 | -0.33 | -0.33 | - | - | - | - | - | - |
Net Income | 23.6% | -508,232,000 | -664,893,000 | -654,588,000 | -586,965,000 | -532,497,000 | -400,640,000 | -384,770,000 | -405,504,000 | -369,648,000 | -321,812,000 | -246,283,000 | -175,348,000 | -116,768,000 | -78,329,000 | -67,851,000 | -71,013,000 | -81,431,000 | -91,770,000 | -84,263,000 | -74,051,000 | -79,133,000 |
Net Income Margin | 100.0% | - | -1.38 | -1.46 | -1.36 | -1.30 | -1.02 | -1.03 | -1.18 | -1.14 | -1.08 | -0.86 | -0.68 | -0.48 | -0.35 | -0.35 | - | - | - | - | - | - |
Free Cashflow | 100.0% | - | -417,570,000 | -386,924,000 | -387,787,000 | -363,195,000 | -309,494,000 | -284,052,000 | -248,944,000 | -191,493,000 | -143,097,000 | -140,100,000 | -111,026,000 | -97,712,000 | -81,723,000 | -65,851,000 | - | - | - | - | - | - |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2017Q4 |
Assets | 21.7% | 1,840 | 1,512 | 1,610 | 1,702 | 1,854 | 2,130 | 2,204 | 2,226 | 2,292 | 2,347 | 2,272 | 1,262 | 1,278 | 948 | 963 | 948 | 940 | 579 | 587 | 345 | 343 |
Current Assets | 26.5% | 1,398 | 1,104 | 1,192 | 1,131 | 1,037 | 1,113 | 1,114 | 1,593 | 1,891 | 2,033 | 1,888 | 1,087 | 1,010 | 607 | 597 | 583 | 604 | 512 | 469 | 297 | 243 |
Cash Equivalents | 21.2% | 271 | 224 | 142 | 158 | 215 | 574 | 492 | 832 | 939 | 869 | 833 | 143 | 165 | 152 | 143 | 147 | 175 | 154 | 141 | 114 | 73.00 |
Inventory | 30.2% | 61.00 | 46.00 | 52.00 | 63.00 | 60.00 | 37.00 | 31.00 | 25.00 | 26.00 | 29.00 | 23.00 | 28.00 | 20.00 | 25.00 | 15.00 | 15.00 | 14.00 | 10.00 | 9.00 | 7.00 | 7.00 |
Net PPE | -4.6% | 156 | 163 | 168 | 168 | 163 | 151 | 124 | 106 | 90.00 | 72.00 | 63.00 | 62.00 | 57.00 | 47.00 | 44.00 | 41.00 | 35.00 | 31.00 | 31.00 | 30.00 | 16.00 |
Goodwill | 0% | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | - | - | - | - | - |
Liabilities | -0.6% | 1,547 | 1,556 | 1,550 | 1,535 | 1,535 | 1,597 | 1,559 | 1,457 | 1,444 | 1,440 | 916 | 114 | 113 | 118 | 115 | 86.00 | 78.00 | 65.00 | 62.00 | 47.00 | 34.00 |
Current Liabilities | -1.6% | 201 | 204 | 193 | 175 | 168 | 229 | 195 | 102 | 97.00 | 96.00 | 67.00 | 72.00 | 70.00 | 82.00 | 73.00 | 68.00 | 57.00 | 48.00 | 47.00 | 32.00 | 20.00 |
Shareholder's Equity | 757.1% | 293 | -44.55 | 60.00 | 167 | 319 | 533 | 645 | 709 | 788 | 847 | 1,298 | 1,092 | 1,115 | 785 | 798 | 815 | 815 | 468 | 483 | 255 | 309 |
Retained Earnings | -4.1% | -1,868 | -1,795 | -1,662 | -1,522 | -1,360 | -1,131 | -1,007 | -916 | -809 | -711 | -606 | -512 | -435 | -380 | -352 | -327 | -314 | -303 | -280 | -255 | -195 |
Additional Paid-In Capital | 23.0% | 2,170 | 1,764 | 1,742 | 1,716 | 1,704 | 1,682 | 1,658 | 1,627 | 1,597 | 1,558 | 1,902 | 1,601 | 1,544 | 1,158 | 1,150 | 1,142 | 1,129 | 771 | 764 | 11.00 | 5.00 |
Shares Outstanding | 14.6% | 118 | 103 | 103 | 102 | 102 | 102 | 102 | 101 | 101 | 101 | 100 | 100 | 96.00 | 94.00 | 94.00 | 93.00 | 89.00 | 86.00 | 30.00 | 12.00 | 13.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | 5.0% | -337 | -355 | -309 | -295 | -270 | -221 | -209 | -191 | -146 | -106 | -103 | -75.05 | -65.64 | -56.11 | -47.13 | -43.33 | -66.72 | -69.93 | -72.18 | -63.64 | -55.45 |
Share Based Compensation | -3.5% | 89.00 | 92.00 | 95.00 | 98.00 | 112 | 121 | 151 | 181 | 202 | 193 | 144 | 92.00 | 43.00 | 20.00 | 17.00 | 14.00 | 11.00 | 9.00 | 7.00 | 6.00 | 5.00 |
Cashflow From Investing | -85.7% | 28.00 | 196 | 150 | -187 | -276 | -76.22 | -63.15 | -94.14 | -61.40 | -514 | -617 | -296 | -317 | -312 | -317 | -538 | -478 | -146 | -153 | -51.16 | -100 |
Cashflow From Financing | 292.7% | 366 | -189 | -189 | -187 | -173 | 3.00 | -66.82 | 976 | 982 | 1,339 | 1,410 | 367 | 373 | 366 | 367 | 615 | 609 | 294 | 293 | 43.00 | 56.00 |
Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 |
Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Revenue: | ||||
Precision oncology testing | $ 125,244 | $ 92,062 | $ 238,637 | $ 176,198 |
Development services and other | 11,906 | 17,082 | 27,227 | 29,045 |
Total revenue | 137,150 | 109,144 | 265,864 | 205,243 |
Costs and operating expenses: | ||||
Cost of precision oncology testing | 49,357 | 34,375 | 94,463 | 65,059 |
Cost of development services and other | 4,491 | 2,352 | 12,458 | 3,649 |
Research and development expense | 90,359 | 85,455 | 183,487 | 167,212 |
Sales and marketing expense | 71,043 | 73,603 | 147,166 | 138,035 |
General and administrative expense | 41,516 | 43,680 | 81,961 | 84,947 |
Total costs and operating expenses | 256,766 | 239,465 | 519,535 | 458,902 |
Loss from operations | (119,616) | (130,321) | (253,671) | (253,659) |
Interest income | 6,727 | 1,387 | 9,787 | 2,165 |
Interest expense | (645) | (645) | (1,289) | (1,289) |
Other income (expense), net | 41,259 | 378 | 39,605 | 330 |
Fair value adjustments of noncontrolling interest liability | 0 | (99,785) | 0 | (99,785) |
Loss before provision for income taxes | (72,275) | (228,986) | (205,568) | (352,238) |
Provision for income taxes | 496 | 446 | 736 | 422 |
Net loss | $ (72,771) | $ (229,432) | $ (206,304) | $ (352,660) |
Net loss per share, basic (in usd per share) | $ (0.67) | $ (2.25) | $ (1.95) | $ (3.46) |
Net loss per share, diluted (in usd per share) | $ (0.67) | $ (2.25) | $ (1.95) | $ (3.46) |
Weighted-average shares used in computing net loss per share , basic (in shares) | 108,808 | 102,047 | 105,752 | 101,950 |
Weighted-average shares used in computing net loss per share, diluted (in shares) | 108,808 | 102,047 | 105,752 | 101,950 |
Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 271,073 | $ 141,647 |
Short-term marketable debt securities | 953,776 | 869,584 |
Accounts receivable, net | 86,468 | 97,256 |
Inventory, net | 60,529 | 51,598 |
Prepaid expenses and other current assets, net | 25,809 | 31,509 |
Total current assets | 1,397,655 | 1,191,594 |
Property and equipment, net | 155,741 | 167,920 |
Right-of-use assets, net | 165,273 | 174,001 |
Intangible assets, net | 10,361 | 11,727 |
Goodwill | 3,290 | 3,290 |
Other assets, net | 107,697 | 61,453 |
Total Assets | 1,840,017 | 1,609,985 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 188,696 | 175,817 |
Deferred revenue | 12,237 | 17,403 |
Total current liabilities | 200,933 | 193,220 |
Convertible senior notes, net | 1,138,678 | 1,137,391 |
Long-term operating lease liabilities | 198,230 | 210,015 |
Other long-term liabilities | 9,450 | 9,179 |
Total Liabilities | 1,547,291 | 1,549,805 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized, no shares issued and outstanding as of June 30, 2023 and December 31, 2022 | 0 | 0 |
Common stock, par value of $0.00001 per share; 350,000,000 shares authorized as of June 30, 2023, and December 31, 2022; 117,662,134 and 102,619,383 shares issued and outstanding as of June 30, 2023, and December 31, 2022, respectively | 1 | 1 |
Additional paid-in capital | 2,169,911 | 1,742,114 |
Accumulated other comprehensive loss | (8,469) | (19,522) |
Accumulated deficit | (1,868,717) | (1,662,413) |
Total Stockholders’ Equity | 292,726 | 60,180 |
Total Liabilities and Stockholders’ Equity | $ 1,840,017 | $ 1,609,985 |